Skip to main content

antibodies Archives

Omicron evades some but not all monoclonal antibodies: study

Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.

Read more


Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

Read more


Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

Read more


Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

Dec. 2, 2021—  by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...

Read more


VUMC researchers a step closer to broad ebolavirus protection

Oct. 28, 2021—  by Bill Snyder A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective against all...

Read more


Zost honored for research on COVID-19, other life-threatening viral diseases

Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

Read more


AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


Autoimmunity advance

Aug. 24, 2021—Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.

Read more


Shared antibodies may push COVID-19 variants: VUMC study

Aug. 10, 2021—Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.

Read more


Chikungunya antibody identified at VUMC moves forward

Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Read more


COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more